| 40.025 0.01 (0.03%) | 10-10 13:16 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 46.75 | 1-year : | 54.6 |
| Resists | First : | 40.02 | Second : | 46.75 |
| Pivot price | 39.89  |
|||
| Supports | First : | 39.34 |
Second : | 38.92 |
| MAs | MA(5) : | 39.97 |
MA(20) : | 39.87 |
| MA(100) : | 37.85 |
MA(250) : | 0 | |
| MACD | MACD : | 0.2  |
Signal : | 0.3 |
| %K %D | K(14,3) : | 99.3 |
D(3) : | 92.4 |
| RSI | RSI(14): 63.5 |
|||
| 52-week | High : | 40.02 | Low : | 28.86 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ VIRS ] has closed below upper band by 21.1%. Bollinger Bands are 72.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 40.03 - 40.17 | 40.17 - 40.3 |
| Low: | 39.61 - 39.8 | 39.8 - 39.97 |
| Close: | 39.74 - 39.99 | 39.99 - 40.22 |
The index is generally composed of U.S.-listed stocks of companies whose products or services help protect against, endure, or recover from biological threats to human health. The Advisor attempts to invest all, or substantially all, of its assets in the component securities that make up the index. It is non-diversified.
Thu, 03 Oct 2024
Disruptive Theme of the Week: Top ETF Themes Through Q3 2024 - ETF Trends
Thu, 01 Aug 2024
Investing in Nobel Prize Achievements – Hepatitis Virus Discovery - Securities.io
Wed, 26 Oct 2022
Here's Why COVID-Themed ETFs May Come Back Under the Radar - Nasdaq
Fri, 21 Jan 2022
ETFs Most Exposed To Netflix’s Epic Sell-Off - Yahoo Finance
Mon, 13 Sep 2021
How to Invest in the Future of Vaccines - Bloomberg.com
Wed, 25 Aug 2021
COVID Biotech ETFs Rise At Fever Pace - ETF.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|